Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study

A. Rayan, H. Hasan
{"title":"Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study","authors":"A. Rayan, H. Hasan","doi":"10.5539/CCO.V6N2P60","DOIUrl":null,"url":null,"abstract":"Background: According to the World Health Organization (WHO), early diagnosis of cancer was associated with increasing rates of survival for cancers as breast, cervix, mouth, larynx, colon, rectum and skin. Still the optimal time to start adjuvant treatment after definitive surgery is uncertainAim of study: to evaluate the impact of delay to start adjuvant treatment in different biologic subtypes of breast cancer on treatment outcomes as regard response, failure free survival (FFS).Patients and methods: It involved 107 patients with nonmetastatic breast cancer presented to clinical oncology department, Assiut university hospital from January 2011 to December 2012, and were eligible for adjuvant systemic treatment, The time from surgery to the start of 1st cycle of adjuvant systemic treatment was calculated, then this time was divided into three time intervals; ≤30 days, >30 - ≤60 days, and >60 days.Results: 41.1%, 45.8%, 13.1% of patients received adjuvant treatment within 30 days, <30-60 days, and more than 60 days respectively, the median failure free survival was 50±2.104 months (95% CI=45.877-54.125) and was significantly decreased with increasing the time but not significantly differed between different time intervals in the whole study patients, nor in different biologic subtypes except luminal B, patients started early adjuvant treatment, relapsed late with significant effect of different time intervals on the time to relapse, local and distant relapses (P<0.000, P<0.001, P<0.02).Conclusion: Adjuvant systemic treatment for breast cancer should be initiated as early as possible better within 30 days of surgery because of significant poor effect of delay to initiate adjuvant treatment on FFS and TTR.","PeriodicalId":89904,"journal":{"name":"Cancer and clinical oncology","volume":"6 1","pages":"60"},"PeriodicalIF":0.0000,"publicationDate":"2017-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5539/CCO.V6N2P60","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5539/CCO.V6N2P60","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: According to the World Health Organization (WHO), early diagnosis of cancer was associated with increasing rates of survival for cancers as breast, cervix, mouth, larynx, colon, rectum and skin. Still the optimal time to start adjuvant treatment after definitive surgery is uncertainAim of study: to evaluate the impact of delay to start adjuvant treatment in different biologic subtypes of breast cancer on treatment outcomes as regard response, failure free survival (FFS).Patients and methods: It involved 107 patients with nonmetastatic breast cancer presented to clinical oncology department, Assiut university hospital from January 2011 to December 2012, and were eligible for adjuvant systemic treatment, The time from surgery to the start of 1st cycle of adjuvant systemic treatment was calculated, then this time was divided into three time intervals; ≤30 days, >30 - ≤60 days, and >60 days.Results: 41.1%, 45.8%, 13.1% of patients received adjuvant treatment within 30 days, <30-60 days, and more than 60 days respectively, the median failure free survival was 50±2.104 months (95% CI=45.877-54.125) and was significantly decreased with increasing the time but not significantly differed between different time intervals in the whole study patients, nor in different biologic subtypes except luminal B, patients started early adjuvant treatment, relapsed late with significant effect of different time intervals on the time to relapse, local and distant relapses (P<0.000, P<0.001, P<0.02).Conclusion: Adjuvant systemic treatment for breast cancer should be initiated as early as possible better within 30 days of surgery because of significant poor effect of delay to initiate adjuvant treatment on FFS and TTR.
乳腺癌开始辅助全身治疗的时机回顾性队列研究
背景:根据世界卫生组织(世界卫生组织)的说法,癌症的早期诊断与乳腺癌、宫颈癌、口腔癌、喉部癌、结肠癌、直肠癌和皮肤癌的存活率增加有关。最终手术后开始辅助治疗的最佳时间仍不确定研究目的:评估不同生物学亚型的癌症延迟开始辅助治疗对治疗结果的影响,无失败生存期(FFS)。患者和方法:涉及2011年1月至2012年12月在阿西尤特大学医院临床肿瘤科就诊的107例非转移性癌症患者,他们有资格接受全身辅助治疗。计算从手术到第一周期全身辅助治疗开始的时间,然后将该时间划分为三个时间间隔;≤30天、>30-≤60天和>60天。结果:41.1%、45.8%、13.1%的患者分别在30天内、<30-60天和60天以上接受了辅助治疗,中位无失败生存期为50±2.104个月(95%CI=45.877-54.125),且随着时间的增加而显著降低,但在整个研究患者中,不同时间间隔之间没有显著差异,在除luminal B外的不同生物亚型中,患者早期开始辅助治疗,晚期复发,不同时间间隔对复发时间有显著影响,结论:由于延迟开始辅助治疗对FFS和TTR的影响显著,癌症的辅助系统治疗应在术后30天内尽早开始,效果更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书